Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The report serves as a notification to the market regarding the company's issued share capital and total voting rights as of October 30, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (25p each) | 5,663,279,551 |
| Treasury Shares | 474,194,158 |
| Total Voting Rights | 5,189,085,393 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. The document reports the static capital position as of the specified date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose of this filing is to establish the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,189,085,393) to determine notification thresholds under Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) which are excluded from voting rights.
- Note that this filing contains no financial performance data for the period.